Clinical trial
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With…
NCT00140621 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00140621 |
|---|---|
| Title | A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease |
| Official title | A Multicenter Open-label Study of the Safety and Efficacy of α-galactosidase A (R-h α-GAL) Replacement Therapy in Patients With Cardiac Fabry Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fabry Disease |
| Intervention type | Drug |
| Interventions | Agalsidase beta |
| Enrollment | 6 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Sep 1, 2005 |
| Last update posted | May 12, 2015 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: